Forschungsprojekte
Ergebnisse pro Seite:
10
2024 - 2022
A Randomized Open Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared To Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma- Dr. med. Markus Munder,
- Prof. Dr. med. Georg Heß
2023 - 2024
Mikrobiologische Performance Qualification der Robotersysteme APOTECAunit und APOTECAsyringe- Prof. Dr. Irene Krämer,
- Dr. Judith Thiesen,
- David Ackermann
2023 - 2030
Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)- Prof. Dr. med. Georg Heß
2023 - 2026
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer- Univ.-Prof. Dr. med. Marcus Schmidt,
- Dr. Katrin Almstedt
2022 - 2026
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle InvasiveBladder Cancer (VOLGA)- PD Dr. med. Maximilian Brandt,
- PD Dr. Rene Mager,
- Dr. Anita Thomas
2022 - 2025
Kompatibilität und Stabilität von applikationsfertigen Parenteralia- Prof. Dr. Irene Krämer,
- Zoe Mittmann,
- Dr. Judith Thiesen
2022 - 2029
Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma- PD Dr. med. habil. Olaf Beck,
- Univ.-Prof. Dr. med. Jörg Faber
2021 - 2024
Entwicklung, Herstellung und Anwendung von Rolapitant-Kapseln zur Prophylaxe der CINV bei Tumorpatienten im Rahmen der pharmazeutischen Betreuung- Prof. Dr. Irene Krämer,
- Tim Hippchen,
- Prof. Dr. Markus Radsak
2021 - 2030
TEDOVA Randomisierte Phase II Studie zum Vergleich eines neo-epitope basierten Vakzin OSE2101 (TEDOPI®) +/- anti-PD1 (Pembrolizumab) versus supportiver Therapie/Beobachtung in der Erhaltungstherapie bei Patientinnen mit platin-sensitiven Ovarialkarzinom-Rezidiv und kontrollierter Erkrankung nach platinbasierter Chemotherapie.- Dr. Anne-Sophie Heimes,
- Univ.-Prof. Dr. Annette Hasenburg